Background: Alpha-fetoprotein has been used as a predictor of recurrence for hepatocellular carcinoma and disease-free survival post-resection. Studies in East Asia have shown that serum alpha-fetoprotein per total tumor volume ratio is a better prognostic indicator than alpha-fetoprotein alone. Similar studies in the United States evaluating serum alpha-fetoprotein to total tumor volume ratio have not been conducted. Its relevance is incompletely understood.
Introduction
Alpha-fetoprotein (AFP) has been used as a predictor of recurrence for hepatocellular carcinoma (HCC) and disease-free survival (DFS) postresection. Serum AFP levels are used commonly to indicate prognostically treatment response, as well as to estimate the severity of tumor burden. 1 Increased AFP levels tend to predict a ✩ Presented at the 2016 Digestive Disease Week.
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poor prognosis, as well as HCC recurrence postresection. 2, 3 A preoperative AFP > 200 ng/ml has been shown previously to be a significant predictor of postoperative recurrence, 4 but AFP levels may be increased in conditions other than HCC, including viral hepatitis, increasing age, and inflammation, as well as other neoplastic processes. 5, 6 Recurrence of HCC after hepatic resection is an important factor affecting the survival of patients with HCC. 7 A variety of factors have been shown to impact the recurrence of HCC postresection including increases in serum AFP preoperatively, large tumor size, multifocal HCC, portal vein invasion, cirrhosis, and hepatitis C https://doi.org/10.1016/j.surg.2017. 10 .063 0039-6060/© 2017 Elsevier Inc. All rights reserved.
Fig. 1.
Tumor volume assessments using VitreaCore 6.7 (Vital Images, Inc, Minnetonka, MN). Semi-automated assessment of tumor volume. The tumor was segmented in a semi-automated fashion using VitreaCore, which displays the segmented volume superimposed over the multiplanar reformatted images ( top left , top right , and bottom right ) and within the volumetric dataset ( bottom left ).
virus (HCV) positivity. 7, 8 Studies in East Asia suggest the AFP to tumor volume ratio may be a better prognostic indicator of HCC recurrence than of AFP alone. Specifically, the AFP to tumor volume ratio has been shown to negatively correlate with overall survival (OS) and DFS. 9 The primary objective of this study was to determine the utility of AFP to total tumor volume (TTV) ratio as a predictor of HCC recurrence postresection in a Western population. Secondarily, this study sought to identify factors predicting HCC recurrence in patients followed at a large tertiary academic medical center.
Materials and Methods

Patient population
We identified all adult patients ( > 18 years of age) with resected HCC between the years 20 0 0 and 2013. During this period, 124 patients were identified, using a prospectively maintained database. We set no specific exclusion criteria.
Data collection
The electronic medical record was used to collect patient data. Patient demographics, associated liver disease, Child-Pugh and Model for End-Stage Liver Disease (MELD) scores, preoperative imaging, preresection treatment, surgical pathology, AFP at diagnosis (AFP1), last AFP before resection (AFP2), and peak AFP levels were recorded. The presence of cirrhosis was evaluated by findings on pathology. The volume of the tumors was calculated with (1) radiologic volumetrics or (2) using the formula ((4/3 ) π r 3 ) where "r" is the mean radius of each lesion. When original preoperative computed tomography (CT) or magnetic resonance imaging (MRI) were available ( n = 70), tumor volume was assessed using VitreaCore 6.7 (Vital Images, Inc, Minnetonka, MN) ( Fig 1 ) . Each imaging set was reviewed and the phase of contrast providing the greatest distinction between tumor and background was selected. The sculpting tool was used to segment each tumor in a semiautomated fashion to provide a measure of tumor volume in milliliters. When original images were not available, the formula discussed earlier was used, and tumor radius was derived from the imaging or pathology report. When both imaging and pathology reports were available, the dimensions on the imaging report were used. The TTV was calculated as the sum of the volumes of all tumors for an individual patient. Peak serum AFP levels were used to calculate the AFP to TTV ratio. Pathology reports were reviewed to assess for tumor differentiation and lymphovascular space invasion (LVSI). Tumor recurrence was defined as pathologically proven, recurrent HCC, or imaging evidence of recurrence on subsequent visits.
Statistical analysis
All statistical analyses were done using SPSS v 22 (IBM SPSS Statistics, IBM Corporation, Armonk, NY). Descriptive statistics for continuous variables (eg, age) included mean, standard deviation, median, and range when appropriate. Categorical variables (eg, sex) were summarized in frequency distribution. Survival statistics were plotted using the Kaplan-Meier curves and analyzed using the log-rank test. Cox regression model was applied for regression analysis. For all comparisons, we set a P value of < .05.
Results
Patient demographics
A total of 124 patients resected for HCC between the years 20 0 0 and 2013 were identified and included in the analysis ( Table 1 ). The mean patient age at the time of resection was 62.7 ± 13 years.
Liver disease
Cirrhosis was present in 21 patients (16.9%). HCV-related cirrhosis was present in 10 patients, 1 had HBV-(hepatitis B virus) related cirrhosis, and 2 had HBV-and HCV-related cirrhosis; 13(10.5%) additional patients had HCV without cirrhosis, and 5 (4.0%) had HBV without cirrhosis ( Table 2 ). The remaining 63.6% of patients had no evidence of pre-existing liver disease. Of the 21 patients with cirrhosis, 16 (76.2%) were Child-Pugh Class A, 4 (19%) were Class B, and 1 was Class C, as assessed at the time of resection. The mean calculated MELD score was 9 ± 3, at the time of resection. None of the patients had a history of encephalopathy, and only 1 had evidence of ascites at the time of resection.
Tumor volume
The majority of patients (106, 85.5%) had solitary tumors. The mean largest tumor diameter was 7.2 cm (range 1.5-25.5 cm). Mean TTV was 327 cm 3 (range 1.2-4905 cm 3 ). Preoperative MRI or CT images were available in 70 (56.5%) patients. In those patients, we performed Bland-Altman analysis and found that tumor volume estimated using average radius and maximum radius had a mean difference of −24.6 ± 1922 cm 3 and 168.3 ± 653.6 cm 3, respectively, as compared with volumetric assessment ( P = .289 and P = 0.035, respectively). Thus, for patients in whom preoperative imaging was unavailable, we estimated tumor volume using average radius rather than maximum radius. A total of 16 (12.9%) patients underwent neoadjuvant treatment. Of those patients, 15 underwent transarterial chemoembolization (TACE) alone, 1 underwent both TACE and radiofrequency ablation (RFA), and 1 had only RFA performed. In terms of resection in the 124 patients, 52 (42%) patients underwent a right hepatectomy, 34 (27%) underwent a left hepatectomy, 30 (24%) underwent segmental resections, 7 (6%) underwent wedge resections, and 1 patient underwent extended right hepatectomy. None of the patients had a prior resection for HCC.
On postresection surgical pathology reports, the tumor was found to be poorly differentiated in 20 (16.1%) cases, welldifferentiated in 36 (29%), and moderately differentiated in 63 (51%). Only 3 cases (2.4%) had the fibrolamellar variant and 1 had undifferentiated pathology; differentiation was not indicated in 1 case. LVSI by the tumor was reported in 56 (45.2%) cases and positive tumor margins were noted in 17 (13.7%) cases. Based on surgical pathology, 70.1% of the tumors were outside the Milan criteria (39.5% were Barcelona clinic liver cancer [BCLC] class B and 30.6% were BCLC class C).
Alpha-fetoprotein levels
Preoperative AFP levels were available in 98 (78%) cases. Mean AFP was 6,744 ng/ml (range 2-160,0 0 0) at AFP1, and 6,237 ng/ml (range 2-160,0 0 0) closest to AFP2. Peak AFP was 8,609 ± 29,018 ng/ml, with a wide range (2-193,112 ng/ml). Mean AFP1 to TTV ratio was 119 ng/ml/cm 3 (range 0.002-7,297); whereas mean AFP2 to TTV ratio was 42.8 ± 163.4 ng/ml/cm 3 (range 0.002-1,342). The range for peak AFP to TTV ratio was 0.002-48,262.
Analysis of tumor recurrence
Of the 124 patients in the study, 48 patients had HCC recurrence. For the management of recurrence, 2 patients underwent salvage liver transplantation; 8 underwent reresection; 10 underwent TACE; 1 underwent RFA; 1 underwent Y90 radioembolization; 2 underwent combination of RFA and TACE; 2 underwent TACE and Y90; 1 underwent TACE, RFA, and Y90; 5 were administered sorafenib, 3 were given unspecified chemotherapy, and 12 were either lost to follow-up, placed in hospice; or died after recurrence. On univariate analysis ( Table 3 ) , peak AFP > 100 ng/ml ( P < .001), LVSI (p.001), peak AFP to TTV ratio > 20 ( P = .001), chronic HCV ( P = .001), AFP2 > 100 ng/ml ( P = .007), cirrhosis ( P = .013), AFP1 > 100 ng/ml ( P = .015) and poor tumor differentiation ( P = .029) were predictive of disease recurrence; however, on multivariate analysis, only peak AFP to TTV ratio > 20 ( P < .001, HR = 3.72, 95% CI [1.82-7.58]) ( Figs 2 and 3 ) , and LVSI ( P = .002, HR = 3.30, 95% CI [1.57-6.94]) were found to affect HCC recurrence-free survival ( Table 4 ) . The 1-, 3-, and 5-year OSs were 76%, 53% and 35%, respectively. HCC recurrence rates were 29%, 54%, and 58% at 1, 3, and 5 years.
Other parameters tested were AFP1 to TTV ratio > 20 ( P = .051), AFP2 to TTV ratio > 20 ( P = .057), age > 65 ( P = .17), Caucasian race ( P = .22), gender ( P = .30), HCC pretreatment ( P = .36), largest tumor diameter > 5 cm ( P = .376), tumor margins positive for the tumor ( P = .761), HBV liver disease ( P = .838), obesity ( P = .85), and multiple tumors ( P = .87); none of these factors affected tumor recurrence on univariate analysis. The rates of recurrence were also analyzed in patients with peak preoperative AFP > 100 (35%), and compared with those who were nonsecretors (65%). Nonsecretors were defined as patients with AFP < 100. Although 30% of nonsecretors developed recurrence, 63% of secretors had recurrent disease ( P < .002). In patients with peak preoperative AFP level and LVSI data available, LVSI was seen in 24/70 (34%) of nonsecretors verus 28/37 (76%) secretors of AFP ( P < .0 0 01).
Discussion
Our study consisting of a large Western population exhibited that peak AFP to TTV ratio > 20 predicted HCC recurrence postresection. It has been suggested that serum AFP directly correlates to tumor size and that AFP-positive HCC has greater cell proliferative activity than AFP-negative HCC. 10, 11 In our study, a greater rate of recurrence was seen in patients who were secretors of AFP (AFP > 100). These factors likely account for the prognostic significance of peak AFP to TTV ratio. Other factors were assessed to evaluate the risk of HCC recurrence after resection. This study confirms previous research identifying LVSI as a risk factor for HCC recurrence. We observed greater rates of LVSI in patients who were secretors of AFP, suggesting that secretion of AFP correlates potentially with more aggressive tumor.
Studies in Asia have evaluated the correlation of AFP in the context of HCC resection and recurrence. One study of patients with a perioperative AFP > 400 ng/ml who underwent hepatic resection showed disease recurrence in patients with postoperative AFP levels > 20 ng/ml. 12 Similar studies assessed patients with preoperative AFP levels > 100 ng/ml, with follow-up levels 3 months after resection. Patients with AFP < 20 ng/ml had a significantly greater DFS (84% versus 18%) 1 year after resection. 13 These studies were small and included only 66 and 58 patients, respectively. A larger study involving 568 patients showed AFP was a highly reliable index for the disease-free state and OS when measured preresection. 14 Finally, a study evaluated 126 patients and showed preoperative AFP > 400 ng/ml, tumor size > 5 cm, and multiple tumors as independent risk factors predicting decreased OS. In addition, vascular invasion was an independent risk factor for OS and DFS postresection. 7 Although the clinical efficacy of using preoperative AFP alone to predict postresection recurrence remains controversial, 1 study sought to identify other means of predicting postresection HCC recurrence. Specifically, an AFP to TTV ratio > 20 was predictive of recurrence within 6 months of resection and may be a better prognostic indicator than AFP alone. 9 Until now, no study has been conducted in the United States evaluating the clinical importance or predictive value of preoperative AFP to TTV ratio as a predictor of HCC recurrence.
Our study demonstrated that a preoperative peak AFP to TTV ratio > 20 was a predictive marker of HCC recurrence after resection. Earlier studies have demonstrated a correlation between ethnicity and HCC. The Asian population has a greater predisposition to develop HCC. 15 Various ethnicities, however, were not assessed. In the future, studies including a more diverse ethnic profile should be conducted. Whether this correlation is applicable to patients treated with chemoradiation rather than resection has not been studied but is another subpopulation needing analysis.
Our study consisted of a predominantly Western population and confirmed the results seen in the Asian study. The risk factors for development of HCC in our population, however, were different. . In Asia, the predominant risk factor was HBV; whereas in our Western population this was not the case. Chronic HCV is the leading risk factor for HCC in the United States. In addition, studies have suggested an increasing incidence of obesity and nonalcoholic fatty liver disease with the development of HCC in the Western population. 16 Because of the variations in risk factors and etiology of HCC in the 2 patient populations, these variations could result in various prognoses.
Our study has several limitations, including the retrospective design and the need to estimate tumor volume rather than being able to measure tumor volume directly in a large portion of our population. As an internal control, however, we compared the estimation of tumor volume against direct measurement with volumetrics in the subset of patients who had imaging available, and we attempted to control for faulty estimation by applying a systematic adjustment. A minority of our patients underwent neoadjuvant therapy. It would be of interest to evaluate the effect of altering the AFP to TTV ratio through neoadjuvant therapy to determine whether outcomes improve in future studies. Finally, not all patients have increased serum levels of AFP, and the role of AFP in detecting recurrences in these patients is not well documented.
Despite the availability of new treatments for HCC and therapies to treat the common risk factors for HCC, it is important to evaluate parameters to screen for recurrence. With the help of such parameters, patients can be risk-stratified in terms of follow-up. Our study demonstrates patients with a preoperative peak AFP to TTV ratio > 20 or evidence of LVSI on pathology are at a greater risk for recurrence and require closer monitoring. Further studies are needed in this patient population to consider the use of intervention (locoregional or chemotherapy) rather than curative resection.
In conclusion, a variety of prognostic values predict the recurrence of HCC postresection. On multivariate analysis, only peak preoperative AFP to TTV ratio > 20 and LVSI predicted HCC recurrence postresection. Our study, consisting of a Western population confirmed the results from prior East Asian studies.
